소화성 궤양 출혈에서 양성자펌프 억제제와 소마토스타틴 병합치료가 예후에 미치는 영향
Does Adding Somatostatin to Proton Pump Inhibitor Improve the Outcome of Peptic Ulcer Bleeding?
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Somatostatin has been shown to offer a distinct advantage over antisecretory drugs in the management of peptic ulcer bleeding (PUB). However, rebleeding rates are still high in spite of endoscopic and medical treatment. In this study, we intended to determine whether combined therapy of a proton pump inhibitor (PPI) plus somatostatin is more beneficial than a PPI alone in patients with PUB. Methods: We enrolled 90 consecutive patients who presented with PUB between January 2006 and October 2007. All the patients were managed with endoscopic hemostasis and divided into two treatment groups: 1) PPI alone (group A) and 2) PPI plus somatostatin (group B). The primary outcome was rebleeding within 72 hours. The secondary outcomes were rebleeding in 30 days, packed red blood cells (pRBC) transfused, length of hospital stay, need for surgery, and in-hospital mortality. Results: Forty-five patients in the PPI group (A) and 45 patients in the PPI plus somatostatin group (B) were studied. There was no difference between the two groups with respect to clinical and endoscopic features at admission. After medical treatment, there was no difference between groups A and B in rebleeding at 72 hours (11% vs. 13%, p = NS), rebleeding in 30 days (13% vs. 16%, p = NS), pRBC transfused (mean, 3.2 vs. 4.5 units, p = NS), length of hospital stay (mean, 7.4 vs. 8.4 days, p = NS), and in-hospital mortality (2% vs. 7%, p = NS). Conclusions: Combined therapy with PPI and somatostatin did not result in better outcomes than PPI alone.
Abstract
Background: Somatostatin has been shown to offer a distinct advantage over antisecretory drugs in the management of peptic ulcer bleeding (PUB). However, rebleeding rates are still high in spite of endoscopic and medical treatment. In this study, we intended to determine whether combined therapy of a proton pump inhibitor (PPI) plus somatostatin is more beneficial than a PPI alone in patients with PUB. Methods: We enrolled 90 consecutive patients who presented with PUB between January 2006 and October 2007. All the patients were managed with endoscopic hemostasis and divided into two treatment groups: 1) PPI alone (group A) and 2) PPI plus somatostatin (group B). The primary outcome was rebleeding within 72 hours. The secondary outcomes were rebleeding in 30 days, packed red blood cells (pRBC) transfused, length of hospital stay, need for surgery, and in-hospital mortality. Results: Forty-five patients in the PPI group (A) and 45 patients in the PPI plus somatostatin group (B) were studied. There was no difference between the two groups with respect to clinical and endoscopic features at admission. After medical treatment, there was no difference between groups A and B in rebleeding at 72 hours (11% vs. 13%, p = NS), rebleeding in 30 days (13% vs. 16%, p = NS), pRBC transfused (mean, 3.2 vs. 4.5 units, p = NS), length of hospital stay (mean, 7.4 vs. 8.4 days, p = NS), and in-hospital mortality (2% vs. 7%, p = NS). Conclusions: Combined therapy with PPI and somatostatin did not result in better outcomes than PPI alone.
참고문헌 (22)
- Longstreth GF, "Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: a population-based study", Am J Gastroenterol, 90, pp.206~210 (1995)
- Laine L, "Bleeding peptic ulcer", N Engl J Med, 331, pp.717~727 (1994)
- Cook DJ, "Endoscopic therapy for acute nonvariceal upper gastrointestinal hemorrhage:a meta-analysis", Gastroenterology, 102, pp.139~148 (1992)
- Sacks HS, "Endoscopic hemostasis. An effective therapy for bleeding peptic ulcers", JAMA, 264, pp.494~499 (1990)
- Adamsen S, "Clinical practice and evidence in endoscopic treatment of bleeding peptic gastroduodenal ulcer", Scand J Gastroenterol, 42, pp.318~323 (2007)
- Patchett SE, "Clot lysis by gastric juice: an in vitro study", Gut, 30, pp.1704~1707 (1989)
- Lau JY, "Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers", N Engl J Med, 343, pp.310~316 (2000)
- Lin HJ, "A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy", Arch Intern Med, 158, pp.54~58 (1998)
- Hsu PI, "Intravenous pantoprazole versus ranitidine for prevention of rebleeding after endoscopic hemostasis of bleeding peptic ulcers", World J Gastroenterol, 10, pp.3666~3669 (2004)
- Leontiadis GI, "Proton pump inhibitor therapy for peptic ulcer bleeding: cochrane collaboration meta-analysis of randomized controlled trials", Mayo Clin Proc, 82, pp.286~296 (2007)
- Sgouros SN, "Somatostatin and its analogues in peptic ulcer bleeding: facts and pathophysiological aspects", Liver Dis, 38, pp.143~148 (2006)
- Coraggio F, "Clinical, controlled trial of somatostatin with ranitidine and placebo in the control of peptic hemorrhage of the upper gastrointestinal tract", Digestion, 43, pp.190~195 (1989)
- Tulassay Z, "Somatostatin versus cimetidine in the treatment of actively bleeding duodenal ulcer: a prospective, randomized, controlled trial", Am J Gastroenterol, 84, pp.6~9 (1989)
- Coraggio F, "Somatostatin in the prevention of recurrent bleeding after endoscopic haemostasis of peptic ulcer haemorrhage: a preliminary report", Eur J Gastroenterol Hepatol, 10, pp.673~676 (1998)
- Forrest JA, "Endoscopy in gastrointestinal bleeding", Lancet, 2, pp.394~397 (1974)
- Wong SK, "Prediction of therapeutic failure after adrenaline injection plus heater probe treatment in patients with bleeding peptic ulcer", Gut, 50, pp.322~325 (2002)
- Khuroo MS, "A comparison of omeprazole and placebo for bleeding peptic ulcer", N Engl J Med, 336, pp.1054~1058 (1997)
- Lau JY, "Omeprazole before endoscopy in patients with gastrointestinal bleeding", N Engl J Med, 356, pp.1631~1640 (2007)
- Avgerinos A, "Somatostatin inhibits gastric acid secretion more effectively than pantoprazole in patients with peptic ulcer bleeding: a prospective, randomized, placebo-controlled trial", Scand J Gastroenterol, 40, pp.515~522 (2005)
- Avgerinos A, "Two different doses and duration schedules of somatostatin -14 in the treatment of patients with bleeding oesophageal varices: a non-randomised controlled study", J Hepatol, 32, pp.171~172 (2000)
- Lin HJ, "Clinical courses and predictors for rebleeding in patients with peptic ulcers and non-bleeding visible vessels: a prospective study", Gut, 35, pp.1389~1393 (1994)
- Lin HJ, "Natural history of bleeding peptic ulcers with a tightly adherent blood clot: a prospective observation", Gastrointest Endosc, 43, pp.470~473 (1996)